ezetimibe has been researched along with simvastatin in 494 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (simvastatin) | Trials (simvastatin) | Recent Studies (post-2010) (simvastatin) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 8,442 | 1,730 | 3,630 |
| Protein | Taxonomy | ezetimibe (IC50) | simvastatin (IC50) |
|---|---|---|---|
| photoreceptor-specific nuclear receptor | Homo sapiens (human) | 1.164 | |
| transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | 4.426 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.7843 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 9.5 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0034 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0034 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0111 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.049 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 6.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 186 (37.65) | 29.6817 |
| 2010's | 278 (56.28) | 24.3611 |
| 2020's | 30 (6.07) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Meng, CQ | 1 |
| Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW | 1 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Affrime, MB; Batra, VK; Cutler, DL; Kosoglou, T; Maxwell, SE; Mellars, L; Meyer, I; Patrick, JE; Statkevich, P; Veltri, EP; Yang, B; Zhu, Y | 1 |
| Császár, A; Márk, L | 1 |
| Bettis, R; Davidson, MH; LeBeaut, AP; Lipka, LJ; McGarry, T; Melani, L; Sun, S; Suresh, R; Veltri, EP | 1 |
| Sacks, FM | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Davidson, MH | 2 |
| Lipka, L; Melani, L; Sager, PT; Strony, J; Suresh, R; Veltri, E; Yang, B | 1 |
| Tellier, P | 1 |
| Simon, HB | 2 |
| Capece, R; Goldberg, AC; Liu, J; Mitchel, YB; Sapre, A | 1 |
| Cho, M; Feldman, T; Insull, W; Koren, M; Kush, D; Lewin, A; McKenney, J; Mitchel, Y; Schrott, H; Shah, S; Sidisin, M | 1 |
| Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J | 1 |
| Murdoch, D; Scott, LJ | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Bays, HE; Donahue, SR; Fraser, N; Johnson-Levonas, AO; Ose, L; Quinto, K; Reyes, R; Sapre, A; Tribble, DL | 1 |
| Gaudiani, LM; Lewin, A; Meneghini, L; Mitchel, Y; Perevozskaya, I; Plotkin, D; Shah, S | 1 |
| Bennett, S; Lipka, L; Melani, L; Sager, P; Suresh, R; Veltri, E | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Schäfer, J | 1 |
| Davidson, MH; Toth, PP | 1 |
| Capece, R; Lipka, L; Mitchel, Y; Sager, PT; Strony, J; Suresh, R; Veltri, E; Yang, B | 1 |
| Cho, M; Gagné, C; Gumbiner, B; Johnson-Levonas, AO; Masana, L; Mata, P; Meehan, A; Sirah, W; Troxell, JK | 1 |
| Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG | 1 |
| de Groot, E; Kastelein, JJ; Sager, PT; Veltri, E | 1 |
| Abate, N; Ballantyne, CM; King, TR; Palmisano, J; Yuan, Z | 1 |
| Bahlmann, F; de Groot, K; Drexler, H; Fauler, G; Fischer, D; Fliser, D; Kirchhoff, N; Landmesser, U; Manes, C; März, W; Mueller, M; Schulz, S; Spiekermann, S | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Alings, AM; Allen, C; Banai, S; Brohet, C; Davies, MJ; Massaad, R | 1 |
| Allen, C; Davies, MJ; Farnier, M; Massaad, R; Volpe, M | 1 |
| Brady, WE; Catapano, A; King, TR; Palmisano, J | 1 |
| Cole, P; Rabasseda, X | 1 |
| McKenney, JM | 1 |
| Chandalia, M; Jialal, I | 1 |
| Füessl, HS | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Kastelein, JJ; Sankatsing, RR | 1 |
| Ballantyne, CM; Brady, WE; Davies, MJ; Feldman, TA; McKenney, J; Mitchel, YB; Palmisano, J; Shah, A | 1 |
| Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O | 1 |
| Adu, D; Altmann, P; Armitage, J; Baigent, C; Ball, S; Baxter, A; Blackwell, L; Cairns, HS; Carr, S; Collins, R; Kourellias, K; Landray, M; Leaper, C; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC | 1 |
| Bergman, A; Gambale, J; Gottesdiener, K; Groff, M; Hreniuk, D; Johnson-Levonas, AO; Kosoglou, T; Lasseter, KC; Laurent, A; Liu, L; Matthews, N; Migoya, EM; Murphy, G; Musson, DG; Paolini, JF; Riffel, K; Roadcap, B; Statkevich, P; Valesky, R; Yi, B; Zhao, JJ | 1 |
| Daskalopoulou, SS; Mikhailidis, DP | 1 |
| Davies, MJ; Maccubbin, D; Mitchel, Y; Ose, L; Rotonda, J; Shah, A; Tribble, D; Veltri, E | 1 |
| Kerzner, B; Rodney, RA; Strony, J; Sugimoto, D; Suresh, R; Veltri, E; Wagman, B; Yang, B; Zieve, F | 1 |
| Ahmed, MH; Osman, MM; Saad, RA | 1 |
| Davidson, M; Feldman, T; Maccubbin, D; Meehan, A; Mitchel, Y; Shah, A; Tribble, D; Veltri, E; Zakson, M | 1 |
| Hughes, EA; Patel, JV | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Andrews, JD; Barrett, PH; Edwards, JY; Huff, MW; Sutherland, BG; Telford, DE | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Allen, C; Boman, K; Chambers, J; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, VA; Malbecq, W; Nienaber, C; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Alonso K, R; Arteaga Ll, A; Castillo, S; Cuevas M, A; González, F; Mata L, P; Rigotti R, A | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Blaimont, M; Chenot, F; de Meester, A; Descamps, OS; Marcovitch, O; Montant, PF | 1 |
| Balcerak, M; Broncel, M; Chojnowska-Jezierska, J | 1 |
| Vaverková, H | 1 |
| Alsheikh-Ali, AA; Gadarla, MR; Karas, RH; Pullatt, RC; Thompson, PD | 1 |
| Johnson-Levonas, A; Lin, J; Musliner, T; Ose, L; Reyes, R; Shah, A; Tribble, D | 1 |
| Booth, AD; Brown, J; Hall, FC; Mäki-Petäjä, KM; McEniery, CM; Wallace, SM; Wilkinson, IB | 1 |
| Robins, DN | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Berthold, HK; Chamberland, JP; Gouni-Berthold, I; Krone, W; Mantzoros, CS | 1 |
| Berthold, HK; Giannakidou, E; Gouni-Berthold, I; Gylling, H; Hallikainen, M; Ko, Y; Krone, W; Mantzoros, CS; Patel, D; Plat, J; Seedorf, U; Soutar, AK; Stier, S | 1 |
| Farnier, M | 1 |
| Kesäniemi, A | 1 |
| Assmann, G; Gutkin, SW; Kannenberg, F; Musliner, TA; Ramey, DR; Veltri, EP | 1 |
| Berthold, HK; Gouni-Berthold, I; Gylling, H; Krone, W; Laaksonen, R; Lehtimäki, T | 1 |
| Padial, LR | 1 |
| Johnson-Levonas, AO; Musliner, T; Ose, L; Reyes, R; Sapre, A; Tribble, DL | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Hussein, O; Itzkovich, Y; Minasian, L; Shestatski, K; Solomon, L; Zidan, J | 1 |
| Abesadze, IT; Gordeev, ML; Korzhenevskaia, KV; Kozulin, VIu; Nil'k, RIa; Panov, AV; Shliakhto, EV | 1 |
| Allen, C; Brudi, P; Henry, P; Johnson-Levonas, AO; Lim, ST; Lis, K; Massaad, R; Pomykaj, T; Reckless, JP; Vandormael, K | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Greenland, P; Lloyd-Jones, D | 1 |
| Thompson, CA | 1 |
| Akdim, F; Bots, ML; de Groot, E; Duivenvoorden, R; Gaudet, D; Kastelein, JJ; Marais, AD; Sijbrands, EJ; Stalenhoef, AF; Stein, EA; Stroes, ES; Trip, MD; Veltri, EP; Visseren, FL; Zwinderman, AH | 1 |
| Curfman, GD; Drazen, JM; Jarcho, JA; Morrissey, S | 1 |
| Brown, BG; Taylor, AJ | 1 |
| Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van Vark-van der Zee, LC; Visseren, FL | 1 |
| Stein, EA | 1 |
| Jackson, G | 1 |
| Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE | 1 |
| Böhm, F; Pernow, J; Rydén, L; Settergren, M | 1 |
| Law, BM | 1 |
| Barho, C; Bode, C; Darius, H; Hildemann, S; Karmann, B; Pittrow, D | 1 |
| Doggrell, SA | 2 |
| Nissen, SE | 1 |
| Branzi, A; Coccolo, F; Fallani, F; Grigioni, F; Magnani, G; Potena, L; Quarta, CC; Russo, A; Scalone, A | 1 |
| Dallinga-Thie, GM; Hajer, GR; van Vark-van der Zee, LC; Visseren, FL | 1 |
| Blumenthal, RS; Musunuru, K | 1 |
| Al-Tamimi, O; Bakir, S; Bazargani, N; Binbrek, A; Gopal, R; Shakir, DK; Zubaid, M | 1 |
| Einecke, D | 2 |
| Davidson, M; Robinson, JG | 1 |
| Alemao, E; Davies, GM; Hildebrandt, P; Keiding, H | 1 |
| Desai, A; Resnic, FS | 1 |
| Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A | 1 |
| Michałek, A | 1 |
| Brown, WV; Harrison, DG; Raggi, P | 1 |
| Mandell, BF | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Steinberg, D | 1 |
| Farnier, M; Kush, D; Mitchel, YB; Perevozskaya, I; Taggart, WV | 1 |
| Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van der Graaf, Y; Visseren, FL | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Eichhorn, EJ | 1 |
| Diamond, GA; Kaul, S | 1 |
| Connor, WE | 1 |
| Blake, JA | 1 |
| Kaye, T | 1 |
| Dixit, RP; Nagarsenker, MS | 1 |
| Barho, C; Bode, C; Darius, H; Hildemann, SK; Karmann, B | 1 |
| Khanmoradi, K; Levi, DM; Pyrsopoulos, NT; Schiff, ER; Selvaggi, G; Tuteja, S; Tzakis, AG; Weisbaum, G; Wolowich, WR | 1 |
| Berthold, HK; Nitschmann, S | 1 |
| D'Agata, BM; Scardi, S; Umari, P | 1 |
| Baigent, C; Califf, R; Clare, R; Collins, R; Emberson, J; Landray, M; Peto, R | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Curfman, GD; D'Agostino, RB; Drazen, JM; Morrissey, S; Ware, JH | 1 |
| Fleming, TR | 1 |
| Abdel-Wahab, M; Geist, V; Herrmann, L; Khattab, AA; Liska, B; Richardt, G; Tölg, R; Westphal, R | 1 |
| Bays, H; Capece, R; Liu, J; Sapre, A; Taggart, W; Tershakovec, A | 1 |
| Cox, A | 1 |
| Hamilton-Craig, IR | 1 |
| de Bree, P; Doevendans, PA; Hajer, GR; Hoefer, IE; Olijhoek, JK; Rafii, S; Verhaar, MC; Visseren, FL; Westerweel, PE | 1 |
| Hanson, ME; Strony, J; Veltri, EP; Yang, B | 1 |
| Avis, HJ; Cuffie-Jackson, C; Gagné, C; Kastelein, JJ; Shi, G; Trip, MD; van der Graaf, A; Veltri, E; Vissers, MN | 1 |
| Spence, JD | 1 |
| Fee, WH | 1 |
| Flaim, JD; Geary, RS; Riley, GC; Tribble, DL; vanVliet, AA; Wedel, MK; Yu, RZ | 1 |
| Chen, JH; Liao, JK; Lin, LJ; Liu, PY; Liu, YW | 1 |
| Porat, G | 1 |
| Gandhi, MJ | 1 |
| Pazianas, M | 1 |
| Böhm, F; Hjemdahl, P; Malmström, RE; Pernow, J; Settergren, M | 1 |
| Hanson, M; Hoffman, R; Strony, J; Veltri, E | 1 |
| Aragoncillo, P; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Granados, R; Muñoz-Pacheco, P | 1 |
| Averna, M; Brudi, P; Farnier, M; Johnson-Levonas, AO; Massaad, R; Missault, L; Vandormael, K; Vaverkova, H; Viigimaa, M | 1 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Farmer, JA | 2 |
| Couture, P; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Gibbons, P; Lütjohann, D; Musliner, T; Reber, M; Sapre, A; Sudhop, T; Taggart, W; Tribble, D; von Bergmann, K | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Ashikaga, H; Blumenthal, RS; Jones, SR | 1 |
| Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A | 1 |
| Al-Omar, M; Hefnawy, M; Julkhuf, S | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE | 1 |
| Böhm, F; Kalani, M; Pernow, J; Rydén, L; Settergren, M | 1 |
| Colquhoun, D; Hamilton-Craig, I; Kostner, K; Woodhouse, S | 1 |
| Blazing, MA; Califf, RM; Harrington, RA | 1 |
| de Lorgeril, M | 1 |
| Visseren, FL; Westerink, J | 2 |
| Pasternak, RC; Tershakovec, AM; Veltri, EP | 1 |
| Pernow, J; Rydén, L; Settergren, M | 1 |
| Choi, BS; Hwang, HS; Hyoung, BJ; Jeon, YJ; Kim, YS; Lee, SY; Song, JC; Yang, CW; Yoon, HE | 1 |
| Alexopoulos, D; Efthimiadis, A; Migdalis, I; Mikhailidis, DP; Pappas, S; Vlasserou, F | 1 |
| Tomkin, GH | 1 |
| Abdalla, DS; Araujo, DB; Bertolami, MC; Bricharello, LP; Faludi, AA; Ferreira, WP; Nakamura, Y | 1 |
| Groen, AK; Hutten, BA; Jakulj, L; Kastelein, JJ; Lutjohann, D; Veltri, EP; Vissers, MN | 1 |
| Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A | 1 |
| Chandalia, M; Cohen, JC; Grundy, SM; Hobbs, HH; Lakoski, SG; Lam, C; Lowe, RS; Musliner, TA; Stepanavage, ME; Vega, GL; Xu, F | 1 |
| Mach, F; Montecucco, F; Quercioli, A | 1 |
| Charland, SL; Malone, DC | 1 |
| Nissen, SE; Taylor, AJ | 1 |
| Mitka, M | 1 |
| Ozaltin, N; Yardimci, C | 1 |
| Anagnostopoulou, K; Christopoulou-Cokkinou, V; Cokkinos, DV; Galea, V; Kolovou, G; Kostakou, P; Mihas, C; Theodoridis, T | 1 |
| Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE | 1 |
| Batista, MC; Ferreira, SR; Kater, AL | 1 |
| Briseño, GG; Mino-León, D | 1 |
| Rodondi, N | 1 |
| Ahmed, MH | 1 |
| Chambers, JB; Viljoen, A; Wierzbicki, AS | 1 |
| Carabello, BA | 1 |
| Cramariuc, D; Gerdts, E; Rieck, AE; Tuseth, N; Wachtell, K | 1 |
| Ashfaq, H; Bregman, DB; Chirinos, JA; Iqbal, N; Khayyam, U; Williams, MM | 1 |
| Ahn, Y; Baek, JY; Cho, JG; Cho, JS; Her, SH; Hong, YJ; Jeong, MH; Jin, SW; Kang, JC; Kim, HD; Kim, JH; Lim, KS; Park, JC; Sim, DS; Yoon, HJ | 1 |
| Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lund, BP; Rieck, AE; Rossebø, AB | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Berneis, K; Berthold, HK; Gouni-Berthold, I; Krone, W; Rizzo, M; Spinas, GA | 1 |
| Boman, K; Brudi, P; Egstrup, K; Gohlke-Baerwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Pedersen, TR; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Bahlmann, E; Chambers, J; Cramariuc, D; Eriksen, E; Gerdts, E; Gohlke-Baerwolf, C; Kuck, KH; Nienaber, CA; Ray, S; Wachtell, K | 1 |
| Belviso, A; Bossi, AC; Cattaneo, D; Diadei, O; Ene-Iordache, B; Ferrari, S; Iliev, I; Parvanova, A; Remuzzi, G; Rota, S; Ruggenenti, P; Trevisan, R | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 2 |
| Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Gensini, GF; Hanson, ME; Le Grazie, C; Rotella, CM; Zaninelli, A | 1 |
| Alexanderson, E; Alexanderson, G; Calleja, R; García-Rojas, L; Jácome, R; Jiménez, M; Martínez, A; Meave, A; Ochoa, JM | 1 |
| Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM | 1 |
| Katsiki, N; Mikhailidis, DP; Sarigianni, M | 2 |
| Montgomery, BD | 1 |
| Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA | 1 |
| Choke, E; Cockerill, GW; Dawson, JA; Loftus, IM; Thompson, MM | 1 |
| Balaji, S; Sunitha, A | 1 |
| Vega de Céniga, M | 1 |
| Breuer, HW | 1 |
| Schunn, H | 1 |
| Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F | 1 |
| Friedrich, DA | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Hanson, ME; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 1 |
| Krumholz, HM | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, C; Pedersen, TR; Ray, S; Rossebø, AB; Skjærpe, T; Wachtell, K; Willenheimer, R | 1 |
| Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y | 1 |
| Elisaf, MS; Florentin, M; Liberopoulos, EN; Moutzouri, E; Rizos, CV; Tselepis, AD | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Krysiak, R; Okopien, B | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Jander, N; Kesäniemi, YA; Malbecq, W; Minners, J; Neumann, FJ; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, A; Skjærpe, T; Wachtell, K; Willenheimer, R | 1 |
| Betteridge, DJ; Brudi, P; Farnier, M; Guyton, JR; Johnson-Levonas, AO; Leiter, LA; Lin, J; Shah, A | 1 |
| Campos, AH; Cavalcanti, AB; de Lemos, JA; Fernandes, JL; Maranhão, RC; Martins, HS; Nicolau, JC; Pesaro, AE; Serrano, CV; Souza, HP | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Krysiak, R; Okopień, B; Zmuda, W | 3 |
| Davis, HR; Lowe, RS; Neff, DR | 1 |
| Cerda, A; Curi, R; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Cardoso, SM; da Silva, PM | 1 |
| Mann, MK | 1 |
| Annuzzi, G; Bozzetto, L; Cipriano, P; Corte, GD; Mangione, A; Patti, L; Riccardi, G; Rivellese, AA | 1 |
| Barnes, JP; Friedman, HS; Rajagopalan, S; Roseman, H | 1 |
| Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA | 1 |
| Pasutharnchat, N; Phanthumchinda, K | 1 |
| Machnik, A; Potaczek, DP; Tracz, W; Undas, A; Wypasek, E; Zmudka, K | 1 |
| Kim, PS; Rosenblatt, M | 1 |
| Forge, BH | 1 |
| Anderson, JD; Berr, SS; Chew, JD; Christopher, JM; DiMaria, JM; Epstein, FH; Hagspiel, KD; Harthun, NL; Hunter, JR; Kramer, CM; Meyer, CH; Wang, H; West, AM; Winberry, GB | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Agodoa, L; Armitage, J; Baigent, C; Baxter, A; Bray, C; Cass, A; Chen, Y; Chen, Z; Collins, R; Craig, J; Dasgupta, T; de Zeeuw, D; Emberson, J; Feldt-Rasmussen, B; Fellström, B; Gaziano, M; Grimm, R; Grobbee, D; Grönhagen-Riska, C; Herrington, W; Hill, M; Holdaas, H; Hooi, LS; Jiang, L; Kasiske, B; Knott, C; Krairittichai, U; Krane, V; Landray, MJ; Levin, A; Lewis, D; Mafham, M; Majoni, W; Massy, ZA; Neal, B; Ophascharoensuk, V; Parish, S; Pedersen, T; Reith, C; Simpson, D; Sleight, P; Tesar, V; Tobert, J; Tomson, C; Walker, R; Wallendszus, K; Wanner, C; Wheeler, DC; Wiecek, A; Young, A | 1 |
| Jardine, AG; Stevens, KK | 1 |
| Chen, ZC; Huang, JC; Kwok, CF; Lee, TY; Lin, CM; Liou, MJ; Liu, RT; Pei, D | 1 |
| Chong, E; Poh, KK; Shen, L | 1 |
| Barbosa, CP; Bersani-Amado, CA; Bracht, A; Bracht, L; Caparroz-Assef, SM; Cuman, RK; Ishii-Iwamoto, EL | 1 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Cioffi, G; Cramariuc, D; Dalsgaard, M; Davidsen, ES; de Simone, G; Egstrup, K; Gerdts, E | 1 |
| Anderson, JD; Berr, SS; Christopher, JM; Dimaria, JM; Epstein, FH; Hagspiel, KD; Harthun, NL; Hunter, JR; Kramer, CM; Meyer, CH; Wang, H; Weltman, AL; West, AM | 1 |
| Jones, WS; Krucoff, MW; Patel, MR | 1 |
| Bae, JW; Choi, CI; Jang, CG; Kim, MJ; Lee, SY; Lee, YH | 1 |
| Elisaf, M; Kei, AA; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H; Moutzouri, E | 1 |
| Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A | 1 |
| Hoffmann, MM; Jacob, S; Konrad, T; Müller-Schewe, T; Winkler, K | 1 |
| Boman, K; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Kesäniemi, YA; Køber, L; Nienaber, C; Ray, S; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Lyseng-Williamson, KA | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 1 |
| Carru, C; Deiana, L; Loriga, G; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| Martin, PY; Saudan, P | 1 |
| Attitalla, IH | 1 |
| Boman, K; Devereux, RB; Gerdts, E; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Ray, S; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Babageorgakas, P; Bouchliou, I; Kotsianidis, I; Margaritis, D; Miltiades, P; Nakou, E; Spanoudakis, E; Stakos, DA; Tziakas, DN | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Bang, CN; Boman, K; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Nienaber, CA; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Prasad, V; Vandross, A | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Green, D; McDonald, J; O'Riordan, E; Panayotova, R; Ritchie, JP | 1 |
| Leung, AA; van Walraven, C | 1 |
| Boman, K; Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Rieck, ÅE; Rossebø, AB; Staal, EM | 1 |
| Chechetkin, AV; Filippov, AE; Kozobova, AI; Popova, NN; Vashchenko, TN; Vashchenko, VI; Vil'ianinov, VN | 1 |
| Almquist, T; Farndale, RW; Hjemdahl, P; Jacobson, SH; Lins, PE | 1 |
| Borges, NC; Figueiredo-Neto, AM; Fonseca, FA; França, CN; Helfenstein, T; Izar, MC; Kasmas, SH; Moreira, FT; Moreno, RA; Ramos, SC | 1 |
| Berneis, K; Berthold, HK; Gouni-Berthold, I; Krone, W; Mantzoros, CS | 1 |
| Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 1 |
| Bahlmann, E; Cioffi, G; Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Ray, S; Rieck, AE | 1 |
| Borthwick, F; Cheeseman, CI; Hassanali, Z; Mangat, R; Proctor, SD; Russell, JC; Uwiera, RR; Vine, DF; Warnakula, S | 1 |
| Freire, I; Lozano, R; Marin, R; Santacruz, MJ | 1 |
| Bianchi, S; Gaspardone, A | 1 |
| Bang, CN; Dalsgaard, M; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Ganesan, S; Ito, MK | 1 |
| Boden, WE; Hartigan, PM; Maron, DJ; Neff, DR; Weintraub, WS | 1 |
| Benjannet, S; Berthold, HK; Gouni-Berthold, I; Seidah, NG | 1 |
| Liu, Y; Mi, SH; Wang, LY; Wang, QH; Wu, WF; Zhang, T | 1 |
| Hegazy, MA; Lotfy, HM | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Brudi, P; Farnier, M; Guyton, JR; Jensen, E; Johnson-Levonas, AO; Polis, AB | 1 |
| Cabré, A; Masana, L; Plana, N | 1 |
| Gerdts, E; Gohlke-Bärwolf, C; Jander, N; Minners, J; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Berman, R; Berthold, HK; Gouni-Berthold, I; Huh, JY; Krone, W; Mantzoros, CS; Spenrath, N | 1 |
| Kaznacheeva, EI; Kheĭmets, GI; Kukharchuk, VV; Liakishev, AA; Miklishanskaia, SV; Vlasik, TN | 1 |
| Hirano, T; Iijima, R; Inazawa, T; Kawamura, M; Kitazawa, T; Kohro, T; Mori, Y; Sakamoto, K; Shiba, T; Tagami, M; Tanaka, A; Yamazaki, T | 1 |
| Elisaf, MS; Liberopoulos, EN; Milionis, HJ; Moutzouri, E; Tellis, CC; Tselepis, AD | 1 |
| Berthold, HK; Ekroos, K; Gouni-Berthold, I; Hurme, R; Kauhanen, D; Kleber, ME; Laaksonen, R; März, W; Suoniemi, M; Sylvänne, T; Tarasov, K | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Ballantyne, CM; Brunner, G; Chen, C; Dong, JF; Hoogeveen, RC; Kougias, P; Kumar, A; Lin, PH; Lumsden, AB; Morrisett, JD; Murray, T; Nambi, V; Negi, SI; Sun, W; Taylor, A; Virani, SS; Yang, EY | 1 |
| Che, W; Liu, B; Wang, H; Yan, H; Zhu, W | 1 |
| Bach, R; Ball, R; Crespo, A; Cuff, JF; Da, C; Gong, X; Lee, CH; Sherer, EC; Shpungin, J; Welch, CJ | 1 |
| Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL | 1 |
| Chuang, JC; Lopez, AM; Posey, KS; Repa, JJ; Turley, SD; Valasek, MA | 1 |
| Barbosa, CP; Bersani-Amado, CA; Cuman, RK; da Silva, LG; Grespan, R; Hernandes, L; Ritter, AM | 1 |
| Machado Cesar, LA; Mangili, LC; Mangili, OC; Maranhão, RC; Mesquita, CH; Moron Gagliardi, AC; Santos, RD; Schaefer, EJ; Tanaka, A | 1 |
| Ali-Rahmani, F; Connor, JR; Huang, MA; Lee, SY; Schengrund, CL | 1 |
| Baigent, C; Blackwell, L; Emberson, J; Fellström, B; Haynes, R; Herrington, W; Hooi, LS; Landray, MJ; Levin, A; Massy, ZA; Reith, C; Staplin, N; Tesar, V; Walker, R | 1 |
| Berthold, HK; Gouni-Berthold, I; Krone, W; Montalto, G; Rizzo, M; Spenrath, N | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Näsman, P | 1 |
| Pan, XD; Sun, LY; Wang, LY; Wu, WF; Yang, SW | 1 |
| Barbosa, SP; Bianco, HT; Camargo, LM; Fonseca, FA; França, CN; Izar, MC; Lins, LS; Pinheiro, LF | 1 |
| Agodoa, L; Baigent, C; Cass, A; Craig, JC; de Zeeuw, D; Emberson, J; Feldt-Rasmussen, B; Fellström, B; Haynes, R; Herrington, WG; Landray, MJ; Levin, A; Lewis, D; Reith, C; Walker, R; Wheeler, DC | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Fernández-Liz, E; Garrido Mesas, I; Ortí Segarra, C | 1 |
| Bang, CN; Boman, K; Dalsgaard, M; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Cavasin, MA; Chonchol, M; Demos-Davies, KM; Jablonski, K; Keenan, AL; Kendrick, J; Levi, M; Masuda, M; Masuda, R; McKinsey, TA; Miyazaki, M; Miyazaki-Anzai, S; Saunders, SJ | 1 |
| Bang, CN; Boman, K; Cramariuc, D; Dalsgaard, M; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Nienaber, CA; Okin, PM; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; Giugliano, RP; McCagg, A; Musliner, TA; Reist, C; Tershakovec, AM; White, JA | 1 |
| Frazee, SG; Garavaglia, SB; Jackevicius, CA; Krumholz, HM; Levin, R; Novshadian, H; Ross, JS; Stettin, G | 1 |
| Krysiak, R; Marek, B; Okopień, B; Zmuda, W | 2 |
| Bahlmann, E; Boman, K; Chambers, JB; Gerdts, E; Gohlke-Bärwolf, C; Hochholzer, W; Jander, N; Kaufmann, BA; Minners, J; Neumann, FJ; Nienaber, CA; Pedersen, TR; Ray, S; Rossebo, A; Wachtell, K | 1 |
| Ayad, MF; Magdy, N | 1 |
| Basta, N; Bolin, K; Busch-Sørensen, M; Egstrup, K; Emneus, M; Green, A; Iachina, M; Kent, C; Kesäniemi, YA; McNally, R; Pedersen, TR; Ramey, DR; Ray, S; Stavem, K; Willenheimer, R | 1 |
| Gaciong, Z; Lewandowski, J; Puchalska, L; Siński, M; Symonides, B | 1 |
| Bang, CN; Berg, RM; Boman, K; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Køber, L; Nielsen, OW; Nienaber, CA; Okin, PM; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Ambegaonkar, BM; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE | 1 |
| Ciriacks, K; Coly, G; Kidambi, S; Krishnaswami, S; Patel, SB | 1 |
| Basso, RG; Cerda, A; Fajardo, CM; Hirata, MH; Hirata, RD | 1 |
| Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Fabbrocini, G; Handler, MZ; Herskovitz, I; Jimenez, JJ; Kittles, C; Lattouf, C; Miteva, M; Schachner, LA; Tosti, A; Wikramanayake, TC | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Ambegaonkar, BM; Cao, X; Ejzykowicz, F; Mavros, P; Ramey, DR; Sajjan, S; Tunceli, K | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Kowalska, B; Krysiak, R; Okopień, B; Żmuda, W | 1 |
| Kukharchuk, VV; Sumarokov, AB | 1 |
| Packard, C; Stezhka, T | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Alves, C; Cerda, A; Dorea, EL; Fajardo, CM; Genvigir, FD; Gusukuma, MC; Hirata, MH; Hirata, RD; Pinto, GA; Rodrigues, AC | 1 |
| Battaggia, A; Donzelli, A; Font, M; Galvano, A; Molteni, D | 1 |
| Cani, PD; Catry, E; Delzenne, NM; Neyrinck, AM; Pachikian, BD; Salazar, N | 1 |
| Deckers, JW; Simoons, ML | 2 |
| Patel, KR | 1 |
| Caz, V; Gil-Ramírez, A; Largo, C; Marín, FR; Martin-Hernandez, R; Reglero, G; Rodríguez-Casado, A; Ruiz-Rodríguez, A; Soler-Rivas, C; Tabernero, M | 1 |
| Signy, J; Signy, M | 1 |
| Poli, A | 2 |
| Cífková, R; Krajčoviechová, A | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Califf, RM; Cannon, CP; Darius, H; De Ferrari, GM; De Lucca, P; Giugliano, RP; Im, K; Jukema, JW; Lewis, BS; McCagg, A; Musliner, TA; Ophuis, TO; Reist, C; Ruzyllo, W; Tershakovec, AM; Theroux, P; White, JA; Wiviott, SD | 1 |
| Akeroyd, JM; Ballantyne, CM; Gillette, MA; Maddox, TM; Michael Ho, P; Nambi, V; Petersen, LA; Rumsfeld, J; Virani, SS | 1 |
| Frishman, WH | 1 |
| Han, SH; Hayashi, T; Kim, EY; Koh, KK; Lee, Y; Oh, PC; Park, YM; Sakuma, I; Shin, EK | 1 |
| Makris, T; Michalopoulou, H; Skalis, G; Thomopoulos, C; Tsioufis, C | 1 |
| Stiefelhagen, P | 1 |
| Arias-Carvajal, O; Cardona-Muñoz, EG; Miranda-Díaz, AG; Moreno-Ulloa, A; Pacheco-Moisés, FP; Rodríguez-Carrizalez, AD; Román-Pintos, LM; Troyo-Sanromán, R; Villegas-Rivera, G | 1 |
| Ennezat, PV; Guerbaai, RA; Nicot, P | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, JA; Zhou, J | 1 |
| Blumenthal, RS; Martin, SS; Michos, ED | 2 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Baigent, C; Cass, A; Emberson, J; Gray, A; Haynes, R; Herrington, W; Landray, MJ; Mihaylova, B; Morton, RL; Schlackow, I; Staplin, N | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Wallén, H | 1 |
| Koh, KK; Oh, PC; Sakuma, I | 1 |
| Elisaf, MS; Filippatos, TD | 1 |
| Cioffi, G; Cramariuc, D; Devereux, RB; Gerdts, E; Lønnebakken, MT; Pedersen, TR; Rogge, BP; Rossebø, AB | 1 |
| Bersani-Amado, CA; Bracht, A; Bracht, L; Caparroz-Assef, SM | 1 |
| Banach, M; Mikhailidis, DP; Serban, MC | 1 |
| Del Puppo, M; Dotti, MT; Federico, A; Ginanneschi, F; Magni, A; Malandrini, A; Mignarri, A; Monti, L; Santorelli, FM; Tessa, A | 1 |
| Baigent, C; Cass, A; Collins, R; Craig, J; Emberson, J; Gray, A; Haynes, R; Herrington, W; Kent, S; Landray, MJ; Lozano-Kühne, J; Mihaylova, B; Reith, C; Schlackow, I | 1 |
| Bang, CN; Boman, K; Devereux, RB; Gohlke-Bärwolf, C; Greve, AM; La Cour, M; Okin, PM; Pedersen, T; Ray, S; Rossebø, A; Wachtell, K | 1 |
| Lancellotti, P; Pierard, LA; Scheen, AJ | 1 |
| Greco, C; Lina, D; Menozzi, A; Urbinati, S | 1 |
| Goldstein, MR; Mascitelli, L | 2 |
| Cavanaugh, KL; Fagerlin, A; Wright Nunes, JA | 1 |
| Butler, CR; O'Hare, AM | 1 |
| Mahdavi-Fard, A; Nader, ND; Pourafkari, L | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Dellborg, M; Giugliano, RP; Im, K; Isaza, D; Kher, U; Lokhnygina, Y; Lopez-Sendon, J; Murphy, SA; Reist, C; Tershakovec, AM; White, JA | 1 |
| Murphy, J; Wright, RS | 1 |
| Chen, CY; Chen, JW; Chen, JY; Huang, PH; Lin, SJ; Shih, CC | 1 |
| Dobrzynski, JM; Kostis, JB | 1 |
| Alvarez, A; Bañuls, C; de Pablo, C; Diaz-Morales, N; Escribano-Lopez, I; Hernandez-Mijares, A; Rocha, M; Rovira-Llopis, S; Veses, S; Victor, VM | 1 |
| Elisaf, MS; Filippatos, TD; Kei, AA | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Robinson, JG | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, J; Zhou, J | 1 |
| Connolly, JG; Gagne, JJ | 1 |
| Bonga, PB; Munaga, SB; Rao, VS; Sharma, HK; Valluru, RK | 1 |
| Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Correia, LC; Garcia, MM; Góes, PM; Guimarães, AC; Ladeia, AM; Lima, PR; Rodrigues, MG; Silva, Mde L; Silva, PF; Varela, CG | 1 |
| Banach, M; Nikolic, D; Rizzo, M; Toth, PP | 1 |
| Diekmann, J; Farr, M; Horstkotte, D; Mellwig, KP; van Buuren, F | 1 |
| Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A | 1 |
| Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM | 1 |
| Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A | 1 |
| Boman, K; Greve, AM; Kesäniemi, YA; Nielsen, OW; Nienaber, CA; Olsen, MH; Pedersen, TR; Sabbah, M; Sajadieh, A; Wachtell, K; Willenheimer, R | 1 |
| Bahlmann, E; Chambers, JB; Cramariuc, D; Gerdts, E; Gohlke-Baerwolf, C; Jander, N; Kuck, KH; Lønnebakken, MT; Minners, J; Nienaber, CA; Ray, S; Seifert, R | 1 |
| Anderson, ML; Blasi, PR; Dunn, J; Henrikson, NB; Lozano, P; Morrison, CC; Nguyen, M; Whitlock, EP | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Eisen, A; Giugliano, RP; Murphy, SA; Park, JG; White, JA | 1 |
| Ardanaz, E; Arriola, L; Balkau, B; Barroso, I; Boeing, H; Burgess, S; Deloukas, P; Forouhi, NG; Franks, PW; Grioni, S; Kaaks, R; Key, TJ; Langenberg, C; Lotta, LA; Luan, J; McCarthy, MI; Navarro, C; Nilsson, PM; O'Rahilly, S; Overvad, K; Palli, D; Panico, S; Perry, JRB; Quirós, JR; Riboli, E; Rolandsson, O; Sacerdote, C; Salamanca, EC; Sattar, N; Savage, DB; Scott, RA; Sharp, SJ; Slimani, N; Spijkerman, AM; Stewart, ID; Tjonneland, A; Tumino, R; van der A, DL; van der Schouw, YT; Wareham, NJ; Willems, SM | 1 |
| Catapano, AL; Farnier, M; Foody, J; Hanson, ME; Jensen, E; Musliner, TA; Polis, AB; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Barrera-Durán, C; González-Ortiz, M; Hernández-Salazar, E; Martínez-Abundis, E | 1 |
| Alfaqih, MA; Barry, WT; Dambal, SK; Dewhirst, MW; Freedland, AR; Freedland, SJ; Freeman, MR; Macias, E; Masko, EM; Muehlbauer, MJ; Newgard, CB; Phillips, TE; Pizzo, SV; Poulton, SH; Sanders, SE; Solomon, KR; Sun, S; Valilis, NA | 1 |
| Ballantyne, CM; Blazing, MA; Braunwald, E; Cannon, CP; de Lemos, JA; Giugliano, RP; Lewis, BS; Lokhnygina, Y; McCagg, A; Musliner, TA; Reist, C; Tershakovec, AM; Tonkin, A; White, JA | 1 |
| Ferreira, AM; Marques da Silva, P | 1 |
| Agodoa, L; Baigent, C; Emberson, J; Haynes, R; Herrington, W; Judge, PK; Landray, MJ; Lewington, S; Mafham, M; Reith, CA; Staplin, N; Tomson, C; Walker, R; Wheeler, DC; Wiecek, A | 1 |
| Ames, FQ; Barbosa, CP; Bersani-Amado, CA; Bracht, L; de Souza Silva-Comar, FM; Tronco, RP | 1 |
| Frydrychowicz, C; Mueller, W; Pasieka, B; Petros, S; Pierer, M; Weidhase, L | 1 |
| Blazing, MA; Bohula, EA; Brady, AJ; Braunwald, E; Cannon, CP; Giugliano, RP; He, P; Kesaniemi, YA; Mitchel, Y; Morrow, DA; Murphy, SA; Park, JG; Pedersen, TR; White, JA | 1 |
| Bergeron, J; Catapano, AL; Krempf, M; Lee, LV; Louie, MJ; Thompson, D | 1 |
| Filipiak, KJ; Kapłon-Cieślicka, A; Kołtowski, Ł; Michalak, M | 1 |
| March Pujol, MA; Martínez-Castelao, A; Travé Mercadé, P; Vía Sosa, MÀ | 1 |
| Daugherty, SL; Downs, JR; Maddox, TM; Masoudi, FA; Rumsfeld, JS; Tang, F; Virani, SS | 1 |
| Bahlmann, E; Boman, K; De Simone, G; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Rossebø, AB; Saeed, S | 1 |
| Cioffi, G; Cramariuc, D; Einarsen, E; Gerdts, E; Mancusi, C; Midtbø, HB; Thomassen, HK | 1 |
| Alahmari, A; Almalki, ZS; Alotaibi, N; Guo, JJ; Thaibah, H | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MAEM | 1 |
| DuBroff, RJ | 1 |
| Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Morrow, DA | 1 |
| Heringer de Souza, F; Sangoi, MDS; Todeschini, V | 1 |
| Blazing, MA; Braunwald, E; Clare, RM; Fanaroff, AC; Giugliano, RP; Lokhnygina, Y; Navar, AM; Roe, MT; Tershakovec, AM; Wiviott, SD | 1 |
| Bernik, MMS; Cerda, A; Dorea, EL; Fajardo, CM; Guimarães, ES; Gusukuma, MC; Hirata, MH; Hirata, RDC; Pinto, GA | 1 |
| Bang, CN; Boman, K; Devereux, RB; Egstrup, K; Greve, AM; Nienaber, C; Okin, PM; Ray, S; Rossebø, AB; Wachtell, K | 1 |
| Carecchio, M; Del Puppo, M; Di Bella, D; Dotti, MT; Magistrelli, L; Mignarri, A; Monti, L | 1 |
| Alves, CMR; Berwanger, O; Bianco, HT; Caixeta, A; Carvalho, ACC; Damiani, LP; Fonseca, FAH; Fonseca, HA; França, CN; Izar, MC; Klassen, A; Maugeri, IML; Moreira, FT; Pinto, IM; Soriano Lopes, A; Szarf, G; Tavares, MFM | 1 |
| Bang, CN; Best, P; Boman, K; Egstrup, K; Forman, JL; Greve, AM; Kesäniemi, YA; Pedersen, TR; Rajamannan, NM; Ray, S; Wachtell, K | 1 |
| Su, XJ; Wang, XH; Zhang, P | 1 |
| Chen, Y; Liu, L | 1 |
| Bang, CN; Boman, K; Eugen-Olsen, J; Forman, JL; Greve, AM; Hodges, GW; Jeppesen, JL; Kesäniemi, YA; Olsen, MH; Ray, S; Wachtell, K | 1 |
| Deloughery, EP; Prasad, V | 1 |
| Adriano, E; Balestrino, M | 1 |
| Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S | 1 |
| Han, SN; Tao, HL; Yang, WH; Yin, JJ; Zhang, LR | 1 |
| Ahmad, T; Blazing, MA; Desai, NR; Lokhnygina, Y; Roe, MT; Sharma, A; Sun, JL | 1 |
| Chen, HJ; Cho, CL; Liang, CL; Liliang, PC; Lu, K; Tsai, YD; Wang, HK; Wang, KW | 1 |
| Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y | 1 |
| Hoang, TX; Knapik-Kowalczuk, J; Paluch, M; Phan, AD; Wakabayashi, K | 1 |
| Gotto, AM | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Califf, RM; Cannon, CP; Giugliano, RP; Jarolim, P; Morrow, DA; Murphy, SA; Park, JG; Qamar, A | 1 |
| Bang, CN; Boman, K; Egstrup, K; Greve, AM; Kesäniemi, YA; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Auer, R; Carballo, D; Carballo, S; Gencer, B; Heg, D; Klingenberg, R; Koskinas, KC; Lüscher, TF; Mach, F; Matter, CM; Nanchen, D; Räber, L; Rodondi, N; Windecker, S | 1 |
| Li, D; McCaw, ZR; Wei, LJ | 1 |
| Bach, RG; Blazing, MA; Cannon, CP | 1 |
| Lütjohann, D; Sijbrands, EJG; Weingärtner, O | 1 |
| Emerson, A; Gonski, P | 1 |
| Abdollahi Kordkandi, S; Babaheidarian, P; Hajializade, M; Mirzaei, A; Moghtadaei, M; Pazoki-Toroudi, H; Yeganeh, A | 1 |
| Al-Shaalan, NH; Nasr, JJM; Shalan, SM | 1 |
| Arora, S; Duvall, WL; Thompson, PD | 1 |
| Fras, Z; Mikhailidis, DP | 1 |
| Hayakawa, EH; Kato, H; Nardone, GA; Usukura, J | 1 |
| Arellano, J; Carrasco, C; García, C | 1 |
| Chen, CC; Chen, HJ; Chen, JS; Liang, CL; Liu, KY; Wang, HK; Wang, KW; Yeh, LR | 1 |
| Bahlmann, E; Chambers, JB; Cramariuc, D; Einarsen, E; Gerdts, E; Midtbo, H | 1 |
| Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M | 1 |
| Benaiges, D; Brea-Hernando, Á; Civeira, F; Climent, E; Lafuente, H; Marco-Benedí, V; Ortega-Martínez de Victoria, E; Pedro-Botet, J; Pintó, X; Plana, N; Suárez-Tembra, M; Vila, À | 1 |
| Bastos, RT; Cruz, ECS; Derogis, PBMC; Dos Santos Ferreira, CE; Faccio, AT; Fonseca, FAH; Fontoura, SC; Izar, MC; Klassen, A; Lopes, AS; Neto, AMF; Picossi, CRC; Sussulini, A; Tavares, MFM | 1 |
| Chmiel, K; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Paluch, M | 1 |
| Bahlmann, E; Cramariuc, D; Einarsen, E; Gerdts, E; Mancusi, C; Midtbø, H; Rossebø, A; Willems, S | 1 |
| Costantini, A; Romagnoli, A; Santoleri, F | 1 |
| Bacchin, ASF; Bianco, HT; Caixeta, A; Damasceno, NRT; Fonseca, FA; França, CN; Izar, MCO; Mello, APQ; Moreira, FT; Neto, AMF; Pinto, LCS; Póvoa, RMS | 1 |
| Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Oyama, K; Park, JG; Sabatine, MS; Tershakovec, AM | 1 |
| Adamson, SS; Biddinger, SB; Bullock, K; Chahar, S; Clish, CB; Crooke, RM; de Ferranti, SD; Gearing, ME; Graham, MJ; Hagey, LR; Kidambi, S; Krawczyk, J; Levenson, AE; Ling, AV; Miao, J; Semova, I; Shin, DJ; Vicent, D; Williams, KA | 1 |
| Chilbert, MR; Clark, CM; Ma, Q; Salah, S; VanDuyn, D | 1 |
| Damasceno, NRT; Fonseca, FAH; Izar, MC; Lotfollahi, Z; Machado, LO; Mathias, AF; Mello, APQ; Neto, AMF; Oliveira, CLP | 1 |
| Cetin, N; Ozyurtlu, F | 1 |
| Hu, YX; Jing, Q; Li, FF; Liang, C; Liang, YL; Qin, YW; You, HM; Zhao, XX; Zhu, RF | 1 |
| Cass, A; Gallagher, M; Hooi, L; Jardine, M; Jun, M; Rogers, K; Smyth, B; Sukkar, L; Talbot, B; Walker, R | 1 |
| Giugliano, RP; Oliver, W | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Liuzzo, G; Pedicino, D | 1 |
53 review(s) available for ezetimibe and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Azetidines; Biological Availability; Body Mass Index; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Ezetimibe; Humans; Male; Middle Aged; Simvastatin | 2002 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cost-Benefit Analysis; Drug Combinations; Drug Interactions; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin | 2004 |
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.
Topics: Azetidines; Cholesterol, HDL; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Lipoproteins, LDL; Simvastatin | 2005 |
Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet.
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Treatment Outcome | 2005 |
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2006 |
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Treatment Outcome | 2006 |
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin | 2007 |
[Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2007 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Simvastatin; Treatment Outcome | 2007 |
Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Simvastatin; Treatment Outcome | 2007 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
Ezetimibe--an update.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hyperlipoproteinemia Type II; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin | 2009 |
Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Ezetimibe/simvastatin.
Topics: Animals; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2009 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
Aortic stenosis and lipids: does intervention work?
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Biomarkers, Pharmacological; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Simvastatin; Stress, Physiological | 2010 |
Effects of ezetimibe on atherosclerosis in preclinical models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Disease Models, Animal; Drug Evaluation, Preclinical; Ezetimibe; Mice; Mice, Knockout; Rabbits; Risk; Simvastatin | 2011 |
Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Simvastatin | 2012 |
Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin | 2012 |
Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Azetidines; Cardiomyopathies; Ezetimibe; Female; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk; Seizures; Simvastatin; Ultrasonography; Warfarin | 2012 |
The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2012 |
[Lipid therapy in daily routine].
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin | 2012 |
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Predictive Value of Tests; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2013 |
Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study.
Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Azetidines; Calcinosis; Comorbidity; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypertension; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Simvastatin; Treatment Outcome | 2013 |
[Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia].
Topics: Anticholesteremic Agents; Azetidines; Drug Synergism; Ezetimibe; Humans; Hyperlipidemias; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
The IMPROVE-IT study and ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2015 |
Dyslipidemia and cardiovascular disease in women.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Contraindications; Dyslipidemias; Estrogen Replacement Therapy; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Menopause; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Simvastatin; Triglycerides; United States | 2015 |
Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Safety; Simvastatin | 2016 |
Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Ezetimibe; Humans; Membrane Proteins; Membrane Transport Proteins; Simvastatin | 2016 |
Statin combination therapy and cardiovascular risk reduction.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Risk Factors; Secondary Prevention; Simvastatin | 2016 |
IMPROVE-IT: what have we learned?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2016 |
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Biomarkers; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mass Screening; Myocardial Infarction; Observational Studies as Topic; Preventive Health Services; Simvastatin; Stroke; United States | 2016 |
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Genetic Association Studies; Genetic Variation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Odds Ratio; Polymorphism, Genetic; Proprotein Convertase 9; Receptors, LDL; Risk; Simvastatin | 2016 |
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Simvastatin | 2017 |
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides | 2018 |
Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.
Topics: Asian People; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin | 2019 |
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin | 2019 |
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2022 |
Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Treatment Outcome | 2023 |
192 trial(s) available for ezetimibe and simvastatin
| Article | Year |
|---|---|
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Azetidines; Biological Availability; Body Mass Index; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Ezetimibe; Humans; Male; Middle Aged; Simvastatin | 2002 |
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Simvastatin; Treatment Outcome | 2002 |
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome | 2004 |
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Risk Factors; Simvastatin; Treatment Outcome | 2004 |
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary
Topics: Administration, Oral; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, LDL; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Tablets; Triglycerides | 2004 |
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Statistics, Nonparametric; Thiazolidinediones | 2005 |
Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Simvastatin | 2005 |
Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Simvastatin; Time Factors | 2005 |
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2005 |
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin | 2005 |
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans.
Topics: Anticholesteremic Agents; Ascorbic Acid; Azetidines; Endothelium, Vascular; Ezetimibe; Female; Hematopoietic Stem Cells; Humans; Lipids; Male; Middle Aged; Radial Artery; Reactive Oxygen Species; Simvastatin; Superoxide Dismutase; Vasodilation | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Simvastatin; Treatment Outcome | 2005 |
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; International Cooperation; Male; Middle Aged; Prospective Studies; Safety; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2005 |
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus | 2006 |
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
Topics: Anticholesteremic Agents; Azetidines; Chronic Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Kidney Diseases; Male; Middle Aged; Simvastatin | 2006 |
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.
Topics: Adolescent; Adult; Analysis of Variance; Anticholesteremic Agents; Area Under Curve; Azetidines; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Reference Values; Simvastatin; Tablets; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2006 |
Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Black or African American; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Safety; Simvastatin; Treatment Outcome | 2006 |
Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome | 2006 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Blood Flow Velocity; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Simvastatin; Stroke Volume; Treatment Outcome; Triglycerides; Ventricular Function, Left | 2007 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Simvastatin; Triglycerides | 2007 |
A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Tablets; Treatment Outcome | 2007 |
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis.
Topics: Aged; Anticholesteremic Agents; Aorta; Arthritis, Rheumatoid; Azetidines; Blood Flow Velocity; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Elasticity; Endothelium, Vascular; Ezetimibe; Female; Humans; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Stress, Mechanical | 2007 |
Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men.
Topics: Adiponectin; Adolescent; Adult; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Leptin; Male; Middle Aged; Resistin; Simvastatin; Time Factors | 2008 |
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lipase; Male; Membrane Proteins; Membrane Transport Proteins; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Receptors, LDL; Serine Endopeptidases; Simvastatin | 2008 |
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Phytosterols; Placebos; Simvastatin; Sitosterols; Sterols | 2008 |
SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Gene Frequency; Genotype; Humans; Hypercholesterolemia; Intestinal Absorption; Male; Polymorphism, Single Nucleotide; Regression Analysis; Simvastatin; Sterol Regulatory Element Binding Protein 1 | 2008 |
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Combinations; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Particle Size; Simvastatin | 2007 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Combinations; Ezetimibe; Fasting; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin | 2008 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin | 2008 |
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Brachial Artery; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation Mediators; Lipids; Male; Middle Aged; Plethysmography; Regional Blood Flow; Simvastatin; Vasodilation | 2008 |
Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2008 |
The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Topics: Adolescent; Adult; Aged; Azetidines; Cross-Over Studies; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin | 2009 |
Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Middle East; Prospective Studies; Simvastatin | 2008 |
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Simvastatin | 2008 |
The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prospective Studies; Simvastatin; Triglycerides | 2008 |
Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Professional Practice; Prospective Studies; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2008 |
[Therapy of familial hypercholesterolemia with or without ezetimibe].
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Carotid Stenosis; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Simvastatin | 2008 |
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome | 2008 |
Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Germany; Humans; Male; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Time Factors | 2008 |
Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cross-Over Studies; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Ezetimibe; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin; Stem Cells | 2008 |
Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Simvastatin; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Simvastatin; Time Factors; Treatment Outcome | 2008 |
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
Topics: Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Azetidines; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Ezetimibe; Humans; Male; Middle Aged; Oligonucleotides; Simvastatin | 2009 |
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Activation; Ezetimibe; Female; Humans; Hyperlipidemias; Leukocytes; Male; Middle Aged; Prospective Studies; rho-Associated Kinases; Simvastatin; Triglycerides; Vasculitis; Vasodilation | 2009 |
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; CD40 Ligand; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Platelet Aggregation; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Arthralgia; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Patient Dropouts; Pravastatin; Respiratory Tract Infections; Simvastatin; Sinusitis; Treatment Outcome; Triglycerides | 2008 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Topics: Adult; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2009 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial).
Topics: Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Prospective Studies; Simvastatin | 2009 |
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Lipoproteins; Male; Placebos; Simvastatin; Treatment Outcome; Triglycerides | 2009 |
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Double-Blind Method; Drug Combinations; Ezetimibe; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Young Adult | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
[Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Waist Circumference | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult | 2009 |
Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Foot; Forearm; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Simvastatin; Skin; Ultrasonography | 2009 |
Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Brachial Artery; C-Reactive Protein; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Ultrasonography; Vasodilation; Young Adult | 2010 |
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Male; Middle Aged; Phytosterols; Simvastatin; Sitosterols; Statistics as Topic | 2010 |
Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides | 2009 |
Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Ezetimibe; Humans; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Simvastatin | 2010 |
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Niacin; Severity of Illness Index; Simvastatin; Tennessee; Time Factors; Treatment Outcome; Vitamin B Complex | 2010 |
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
Topics: Adolescent; Adult; Aged; Anthropometry; Anticholesteremic Agents; Azetidines; Biomarkers; Blood Coagulation; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Middle Aged; Prediabetic State; Simvastatin; Young Adult | 2010 |
The SEAS Trial.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2010 |
Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet: a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Azetidines; Body Weight; Diet, Carbohydrate-Restricted; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Simvastatin; Triglycerides | 2010 |
Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy).
Topics: Aged; Aged, 80 and over; Angiography; Aortic Valve Stenosis; Azetidines; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Logistic Models; Male; Middle Aged; Multivariate Analysis; Obesity; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Simvastatin; Stroke Volume; Systole; Treatment Outcome | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial.
Topics: Adolescent; Adult; Anticholesteremic Agents; Azetidines; Drug Interactions; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Ezetimibe; Humans; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Simvastatin; Young Adult | 2010 |
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Apolipoproteins B; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Simvastatin; Time Factors | 2010 |
Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy.
Topics: Aged; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Azetidines; Drug Therapy, Combination; Echocardiography, Doppler; Europe; Ezetimibe; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recovery of Function; Reproducibility of Results; Severity of Illness Index; Simvastatin; Treatment Outcome; Ventricular Function, Left | 2010 |
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Young Adult | 2010 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Odds Ratio; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Statistics as Topic | 2010 |
A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms.
Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Azetidines; Biopsy; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Interleukins; Lipids; Male; Matrix Metalloproteinases; Pilot Projects; Simvastatin; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tumor Necrosis Factor-alpha | 2011 |
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2010 |
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Treatment Outcome | 2010 |
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Simvastatin; Treatment Outcome | 2010 |
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cross-Over Studies; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Male; Niacin; Nicotinic Acids; Simvastatin; Tablets | 2011 |
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Follow-Up Studies; Greece; Humans; Hypercholesterolemia; Male; Middle Aged; Osmolar Concentration; Particle Size; Simvastatin | 2011 |
The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cytokines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Risk Factors; Simvastatin; Time Factors | 2011 |
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Severity of Illness Index; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2011 |
Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation; Simvastatin | 2012 |
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
Topics: Aged; Apolipoproteins B; Azetidines; Cholesterol; Coronary Disease; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia.
Topics: Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Hemostasis; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome; Young Adult | 2012 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome | 2011 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2011 |
Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Centrifugation, Density Gradient; Cholesterol; Chylomicrons; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Fasting; Female; Humans; Lipoproteins, VLDL; Male; Middle Aged; Placebos; Postprandial Period; Simvastatin; Time Factors; Triglycerides | 2011 |
Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fibrinolysis; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Simvastatin; Treatment Outcome; Young Adult | 2011 |
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Peripheral Arterial Disease; Plaque, Atherosclerotic; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels.
Topics: Anticholesteremic Agents; Azetidines; Cytokines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Lymphocytes; Male; Middle Aged; Prospective Studies; Simvastatin | 2012 |
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Topics: Adult; Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Simvastatin; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Taiwan; Time Factors; Triglycerides | 2011 |
Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Energy Metabolism; Exercise Test; Exercise Tolerance; Ezetimibe; Female; Humans; Leg; Magnetic Resonance Angiography; Magnetic Resonance Spectroscopy; Male; Middle Aged; Muscle, Skeletal; Peripheral Arterial Disease; Phosphocreatine; Simvastatin | 2011 |
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.
Topics: Aged; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fasting; Female; Fluorobenzenes; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Medication Adherence; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2011 |
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Centrifugation, Density Gradient; Diabetes Mellitus, Type 2; Down-Regulation; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2012 |
Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Simvastatin; Ventricular Dysfunction, Left | 2012 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy.
Topics: Aged; Allantoin; Azetidines; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney; Kidney Failure, Chronic; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Simvastatin; Sulfhydryl Compounds; Superoxides; Taurine; Uric Acid | 2012 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardiography; Ezetimibe; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Simvastatin | 2012 |
Statin-induced immunomodulation alters peripheral invariant natural killer T-cell prevalence in hyperlipidemic patients.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunomodulation; Male; Middle Aged; Natural Killer T-Cells; Prevalence; Simvastatin; Triglycerides | 2012 |
Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Atrial Fibrillation; Azetidines; Double-Blind Method; Ezetimibe; Female; Heart Ventricles; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Simvastatin; Stroke; Time Factors; Ultrasonography | 2012 |
Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Azetidines; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Simvastatin | 2012 |
Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Blood Platelets; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Flow Cytometry; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Leukocytes; Lipids; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Prognosis; Risk Factors; Simvastatin; Young Adult | 2012 |
Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein.
Topics: Adult; Anti-Inflammatory Agents; Anticholesteremic Agents; Azetidines; Biomarkers; C-Reactive Protein; Drug Administration Schedule; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Linear Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Simvastatin; Time Factors; Young Adult | 2013 |
Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial).
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Blood Pressure; Double-Blind Method; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Risk Factors; Simvastatin; Stroke Volume; Ventricular Function, Left | 2012 |
Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Atrial Fibrillation; Atrial Function, Left; Azetidines; Blood Flow Velocity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Electrocardiography; Ezetimibe; Female; Heart Atria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Simvastatin; Treatment Outcome | 2013 |
Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Revascularization; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2013 |
Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.
Topics: Adult; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Male; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Simvastatin; Up-Regulation | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo.
Topics: Adult; Azetidines; Cell Survival; Cells, Cultured; Ezetimibe; Female; Fibronectins; Humans; Hypolipidemic Agents; Male; Middle Aged; Muscle, Skeletal; Simvastatin; Young Adult | 2013 |
[Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipid Metabolism; Male; Middle Aged; Severity of Illness Index; Simvastatin; Treatment Outcome | 2013 |
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Sex Factors; Simvastatin | 2013 |
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Azetidines; Cholesterol, LDL; Dinoprost; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
Topics: Aged; Azetidines; Cholesterol; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Femoral Artery; Humans; Lipids; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Simvastatin | 2013 |
Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; rho-Associated Kinases; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Vascular Stiffness | 2013 |
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome | 2014 |
Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects.
Topics: Aged; Azetidines; Cholesterol Esters; Chylomicron Remnants; Chylomicrons; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Kinetics; Male; Middle Aged; Simvastatin; Triglycerides; Triolein | 2014 |
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
Topics: Aged; Anticholesteremic Agents; Azetidines; Catheterization; Cholesterol, LDL; Device Removal; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Reoperation; Simvastatin; Thrombosis; Vascular Access Devices; Vascular Patency | 2014 |
Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.
Topics: Adipokines; Adult; Azetidines; Biomarkers; Drug Therapy, Combination; Ezetimibe; Glucose; Healthy Volunteers; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Male; Simvastatin | 2014 |
Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Chemokine CCL2; Cross-Over Studies; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Inflammation; Inflammation Mediators; Interferon-gamma; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2014 |
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.
Topics: Aged; Anticholesteremic Agents; Aspirin; Azetidines; Cell-Derived Microparticles; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Combinations; Endothelial Progenitor Cells; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Simvastatin; Ticlopidine; Triglycerides | 2014 |
Effects of lowering LDL cholesterol on progression of kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Renal Dialysis; Simvastatin; Treatment Outcome | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Simvastatin; Survival Rate | 2014 |
Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Blood Flow Velocity; Echocardiography; Ezetimibe; Female; Heart Failure; Humans; Male; Prospective Studies; ROC Curve; Simvastatin; Stroke Volume | 2014 |
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Registries; Retrospective Studies; Risk Assessment; Simvastatin; Survival Rate; Time Factors | 2014 |
Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels.
Topics: Adult; Anticholesteremic Agents; Azetidines; Baroreflex; Cholesterol; Cholesterol, HDL; Double-Blind Method; Ezetimibe; Female; Heart Rate; Hemodynamics; Humans; Hypercholesterolemia; Male; Middle Aged; Muscle, Skeletal; Simvastatin; Sympathetic Nervous System | 2014 |
Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Atrial Fibrillation; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Global Health; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Rest; Simvastatin; Survival Rate; Time Factors | 2015 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Healthy Volunteers; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; NF-kappa B; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Taurine; Triglycerides; Tryptophan; Uric Acid | 2015 |
Treatment of alopecia areata with simvastatin/ezetimibe.
Topics: Adult; Aged; Alopecia Areata; Azetidines; Cholinergic Antagonists; Drug Combinations; Ezetimibe; Female; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Remission Induction; Simvastatin; Young Adult | 2015 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
[IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Simvastatin | 2014 |
The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Ezetimibe; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Male; Middle Aged; Rosuvastatin Calcium; Sex Hormone-Binding Globulin; Simvastatin; Steroids; Testis; Testosterone | 2015 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cell Line; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; RNA, Messenger; Simvastatin; Treatment Outcome | 2015 |
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Simvastatin; Triglycerides | 2015 |
[Even lower values are even better!].
Topics: Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Risk Factors; Simvastatin; Stroke | 2015 |
Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Topics: Diabetic Neuropathies; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin | 2015 |
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cerebral Revascularization; Cholesterol, LDL; Comorbidity; Creatinine; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin; Treatment Outcome | 2015 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Topics: Aged; Anticholesteremic Agents; Disease Progression; Educational Status; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Simvastatin; Vascular Diseases | 2016 |
Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Relation of Left Ventricular Mass to Prognosis in Initially Asymptomatic Mild to Moderate Aortic Valve Stenosis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Simvastatin | 2015 |
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin | 2016 |
Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Cataract; Cholesterol, LDL; Denmark; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Norway; Risk Factors; Simvastatin; Sweden; United Kingdom; United States | 2015 |
[ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Simvastatin; Treatment Outcome | 2015 |
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Simvastatin; Survival Rate; Time Factors; Treatment Outcome; United States | 2016 |
Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Cholesterol; Coculture Techniques; Endothelial Cells; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hypercholesterolemia; Leukocytes; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Oxidative Stress; Simvastatin; Spain; Time Factors; Treatment Outcome | 2016 |
[Approval extension for statin plus ezetimib].
Topics: Acute Coronary Syndrome; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2016 |
Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Placebo Effect; Reference Values; Simvastatin; Statistics, Nonparametric; Time Factors; Treatment Outcome; Vasodilation | 2016 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides | 2016 |
Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Blood Pressure; Double-Blind Method; Ezetimibe; Follow-Up Studies; Humans; Hypertension; Middle Aged; Simvastatin | 2016 |
Small aortic root in aortic valve stenosis: clinical characteristics and prognostic implications.
Topics: Aged; Aortic Valve; Aortic Valve Stenosis; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Simvastatin; Survival Rate; Time Factors; Treatment Outcome | 2017 |
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Simvastatin; Treatment Outcome | 2016 |
[Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Inulin; Male; Middle Aged; Simvastatin; Treatment Outcome | 2016 |
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2016 |
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2017 |
Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Norway; Prognosis; Prospective Studies; Risk Factors; Simvastatin; Stroke Volume; Survival Rate; Sweden; Ventricular Function, Left | 2017 |
Echocardiographic aortic valve calcification and outcomes in women and men with aortic stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Echocardiography; Ezetimibe; Female; Humans; Male; Middle Aged; Risk Factors; Severity of Illness Index; Sex Factors; Simvastatin; Treatment Outcome | 2017 |
Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Brain Ischemia; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Quality-Adjusted Life Years; Saudi Arabia; Simvastatin; Treatment Outcome | 2018 |
Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Cause of Death; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Risk Assessment; Risk Factors; Sex Distribution; Simvastatin; Survival Rate; Time Factors; United States | 2017 |
Antihypertensive Treatment With β-Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Blood Pressure; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Heart Ventricles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Morbidity; Propensity Score; Simvastatin; Survival Rate; United States | 2017 |
Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute My
Topics: Adenosine; Anti-Inflammatory Agents; B-Lymphocytes; Biomarkers; Brazil; Clinical Protocols; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enzyme-Linked Immunospot Assay; Ezetimibe; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Magnetic Resonance Imaging; Male; Metabolomics; Platelet Aggregation Inhibitors; Proteomics; Research Design; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction; Stroke Volume; T-Lymphocytes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Survival Rate; Treatment Outcome | 2018 |
Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Topics: Aged; Anticholesteremic Agents; Aorta; Aortic Valve Stenosis; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Constriction, Pathologic; Disease Progression; Ezetimibe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptors, Urokinase Plasminogen Activator; Risk Factors; Simvastatin | 2018 |
Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cause of Death; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; North America; Phenotype; Risk Assessment; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome | 2019 |
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2019 |
Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Asymptomatic Diseases; Biomarkers; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Time Factors; Treatment Outcome | 2019 |
Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Simvastatin | 2020 |
Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).
Topics: Aged; Anticholesteremic Agents; Chronic Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Non-alcoholic Fatty Liver Disease; Simvastatin; Treatment Outcome | 2021 |
Higher Acceleration/Ejection Time Ratio Predicts Impaired Outcome in Aortic Valve Stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prognosis; Prospective Studies; Severity of Illness Index; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Low myocardial energetic efficiency is associated with increased mortality in aortic stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Double-Blind Method; Echocardiography, Doppler; Energy Metabolism; Europe; Ezetimibe; Follow-Up Studies; Humans; Middle Aged; Myocardium; Prognosis; Prospective Studies; Simvastatin; Stroke Volume; Survival Rate; Ventricular Function, Left | 2021 |
Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction.
Topics: Aged; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin | 2021 |
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
Topics: Animals; Bile Acids and Salts; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Liver; Mice; Receptor, Insulin; Simvastatin; Steroid 12-alpha-Hydroxylase | 2022 |
Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.
Topics: Anticholesteremic Agents; Clopidogrel; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Scattering, Small Angle; Simvastatin; Ticagrelor; X-Ray Diffraction | 2022 |
Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review.
Topics: Ezetimibe; Humans; Kidney; Kidney Transplantation; Renal Insufficiency, Chronic; Simvastatin | 2023 |
250 other study(ies) available for ezetimibe and simvastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Ezetimibe (Schering-Plough).
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Azetidines; Bile; Cholesterol; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Down-Regulation; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drugs, Investigational; Ezetimibe; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Molecular Structure; Simvastatin | 2001 |
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Dogs; Drug Combinations; Drug Synergism; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Pravastatin; Simvastatin; Time Factors | 2001 |
[Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Simvastatin; Treatment Outcome | 2002 |
Low-density lipoprotein lowering therapy: an analysis of the options.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscular Diseases; Simvastatin | 2002 |
[Ezetimib plus statin combination. A strong duo].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin | 2002 |
[Lowering cholesterol becomes easier. Combining instead of increasing dosage].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2003 |
[Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2003 |
[Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Humans; Primary Prevention; Risk Factors; Simvastatin | 2003 |
On call. I'm a 63-year-old man with arthritis but no other conditions. My only medicines were Naprosyn and vitamins until my last annual checkup, when my cholesterol was high. My doctor gave me Zocor, which helped. But I developed muscle aches, so he swit
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Male; Middle Aged; Reference Values; Simvastatin | 2004 |
[New combination therapy. Up to 60% lower LDL cholesterol level].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Combinations; Drug Synergism; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2004 |
Vytorin: a combination of ezetimibe and simvastatin.
Topics: Azetidines; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2004 |
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors | 2004 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sex Factors; Simvastatin; Time Factors; Treatment Outcome; Women's Health | 2004 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
[How sure is the combined lipid lowering?].
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2005 |
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENH
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
[Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Guideline Adherence; Humans; Hypercholesterolemia; Intestinal Mucosa; Intestines; Liver; Reference Values; Simvastatin | 2005 |
[Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism].
Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
[Goal in hypercholesterolemia: lowering LDL cholesterol level by 50%].
Topics: Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2005 |
[MMW- Drug Prize 2005 for simvastatin/ezetimib (Inegy). LDL goal values are easier to reach now].
Topics: Aged; Anticholesteremic Agents; Awards and Prizes; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Combinations; Ezetimibe; Female; Germany; Humans; Male; Periodicals as Topic; Risk Factors; Simvastatin | 2005 |
[Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Risk Factors; Simvastatin; Triglycerides | 2005 |
[Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Time Factors | 2005 |
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Dyslipidemias; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Humans; Insulin Resistance; Simvastatin | 2006 |
[Inegy: a powerful new medication for lowering LDL cholesterol].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Ezetimibe; Humans; Simvastatin | 2006 |
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Ezetimibe; Female; Intestinal Mucosa; Intestines; Lipid Metabolism; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Models, Biological; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Swine | 2007 |
[Molecular diagnosis and combined lipid lowering therapy of heterozygous familial hypercholesterolemia. Report of one case].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; LDL-Receptor Related Proteins; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Prognosis; Simvastatin | 2007 |
Tendon rupture associated with simvastatin/ezetimibe therapy.
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Metalloproteases; Middle Aged; Simvastatin; Tendon Injuries; Tendons | 2007 |
[Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infant, Newborn; Practice Guidelines as Topic; Simvastatin; Treatment Outcome | 2007 |
Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy.
Topics: Alopecia Areata; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Hair; Humans; Hyperlipidemias; Male; Middle Aged; Simvastatin | 2007 |
In brief: Zetia and Vytorin: the ENHANCE study.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, LDL; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2008 |
Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Platelet Aggregation; Simvastatin; Treatment Outcome | 2008 |
[Functional state of endothelium and oxidant activity of leucocytes in patients with ischemic heart disease after coronary bypass surgery].
Topics: Adult; Anticholesteremic Agents; Azetidines; Case-Control Studies; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Leukocytes; Luminescent Measurements; Male; Microscopy; Middle Aged; Myocardial Ischemia; Oxidation-Reduction; Severity of Illness Index; Simvastatin; Treatment Outcome | 2007 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Critical lessons from the ENHANCE trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Conflict of Interest; Data Interpretation, Statistical; Drug Approval; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Mass Media; Randomized Controlled Trials as Topic; Simvastatin; Ultrasonography | 2008 |
Lipid-lowering study raises issues of therapy's value.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2008 |
Cholesterol lowering and ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Triglycerides; Tunica Intima; Tunica Media | 2008 |
Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Tunica Media | 2008 |
After ENHANCE: is more LDL cholesterol lowering even better?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin | 2008 |
ENHANCE: food for the ostriches.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Rx for uncertainty. Does a popular cholesterol-lowering drug do what it's supposed to do?
Topics: American Heart Association; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin; United States | 2008 |
Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
Topics: Aged; Ambulatory Care; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Female; Forecasting; Humans; Hypercholesterolemia; Male; Middle Aged; Primary Health Care; Prospective Studies; Risk Assessment; Simvastatin; Treatment Outcome | 2008 |
ENHANCE and ACCORD: controversy over surrogate end points.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Clinical Trials as Topic; Clinical Trials, Phase IV as Topic; Endpoint Determination; Ezetimibe; Glycated Hemoglobin; Humans; Hypercholesterolemia; Research Design; Simvastatin | 2008 |
The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2008 |
[Dual lipid control without anti-atherosclerosis effect].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Is it over for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Controlled Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2008 |
[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Decision Making; Drug Costs; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
[Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Ezetimibe; Humans; Kaplan-Meier Estimate; Life Style; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Highlights from the 57th annual scientific session of the American College of Cardiology.
Topics: Aortic Valve; Azetidines; Cardiac Catheterization; Catheter Ablation; Coronary Disease; Drug-Eluting Stents; Ezetimibe; Heart Failure; Heart Valve Diseases; Humans; Mitral Valve Insufficiency; Simvastatin; Surgical Instruments | 2008 |
[Commentary to the article: Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43 ].
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome | 2008 |
Enhanced hype.
Topics: Administration, Inhalation; Anticholesteremic Agents; Azetidines; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Information Dissemination; Simvastatin; United States | 2008 |
A drug, a concept, and a clinical trial on trial.
Topics: Azetidines; Clinical Trials as Topic; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Humans; Research Design; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Vessels; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin; Tunica Intima | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Reproducibility of Results; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin | 2008 |
Ezetimibe revisited.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Clinical Trials as Topic; Drug Combinations; Endpoint Determination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Azetidines; Chemistry, Pharmaceutical; Cholesterol; Emulsions; Ezetimibe; Male; Microscopy, Electron, Scanning; Nanoparticles; Rats; Rats, Sprague-Dawley; Simvastatin; Solubility; X-Ray Diffraction | 2008 |
Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.
Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Simvastatin | 2008 |
[Lower is better: ENHANCE affair].
Topics: Anticholesteremic Agents; Azetidines; Carotid Artery Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Publication Bias; Simvastatin; Ultrasonography | 2008 |
Analyses of cancer data from three ezetimibe trials.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Ezetimibe and cancer--an uncertain association.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Identifying and addressing safety signals in clinical trials.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Hypercholesterolaemia: Clarifications from adverse drug reactions agency.
Topics: Anticholesteremic Agents; Azetidines; England; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2008 |
After ENHANCE: the cholesterol hypothesis is alive and well.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Is carotid intima-media thickness a reliable clinical predictor?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Uncertainty dogs Zetia and Vytorin.
Topics: Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin; Uncertainty | 2008 |
On call. I don't understand the problem with Vytorin. The two components when used separately work fine, but when mixed together things change. Why?
Topics: Azetidines; Clinical Trials as Topic; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hypolipidemic Agents; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
Does 'ENHANCE' diminish confidence in ezetimibe?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Simvastatin | 2008 |
Calcific aortic stenosis.
Topics: Animals; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Ezetimibe; Humans; Models, Biological; Renal Insufficiency, Chronic; Simvastatin | 2009 |
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Line; Cell Movement; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Male; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial).
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Lipids; Simvastatin | 2009 |
Utility of ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Treatment Outcome | 2009 |
Rapid and sensitive simultaneous determination of ezetimibe and simvastatin from their combination drug products by monolithic silica high-performance liquid chromatographic column.
Topics: Anticholesteremic Agents; Azetidines; Chromatography, High Pressure Liquid; Drug Combinations; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Reproducibility of Results; Simvastatin; Tablets | 2009 |
At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Lipoproteins, LDL; Male; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Simvastatin | 2009 |
Premature release of data from clinical trials of ezetimibe.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Databases as Topic; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Registries; Simvastatin; United States | 2009 |
Letter by Westerink and Visseren regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Simvastatin; Vasculitis | 2009 |
Letter by Tershakovec et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Risk Factors; Simvastatin; Vasculitis | 2009 |
Letter by Settergren et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Simvastatin; Vasculitis | 2009 |
The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients.
Topics: Adult; Azetidines; C-Reactive Protein; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Simvastatin | 2009 |
Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Prospective Studies; Simvastatin | 2009 |
Ezetimibe - new anti-atherogenic properties?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Movement; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin | 2010 |
Preliminary observations from preliminary trial results: have we finally had enough?
Topics: Adult; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Surgical Procedures; Ezetimibe; Heart Failure; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Reperfusion Injury; Research Design; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Practice Patterns, Physicians'; Risk Factors; Simvastatin; Treatment Outcome; Ultrasonography; United States; United States Food and Drug Administration | 2010 |
Simultaneous determination of ezetimibe and simvastatin in pharmaceutical preparations by MEKC.
Topics: Anticholesteremic Agents; Azetidines; Calibration; Chromatography, Micellar Electrokinetic Capillary; Diflunisal; Ezetimibe; Limit of Detection; Pharmaceutical Preparations; Simvastatin | 2010 |
Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; C-Reactive Protein; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Simvastatin; Thromboplastin; Time Factors; Treatment Outcome; von Willebrand Factor | 2010 |
Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
Topics: Aged; Azetidines; Cost-Benefit Analysis; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mexico; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
[How far the rates of cholesterol have to be lowered in primary prevention?].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Risk Factors; Simvastatin | 2010 |
Ezetimibe and recent clinical trials: a look on the bright side.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Niacin; Placebos; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2010 |
Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy).
Topics: Aortic Valve Stenosis; Azetidines; Biomarkers; Cardiomegaly; Cardiomyopathy, Hypertrophic; Ezetimibe; Female; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Simvastatin | 2010 |
Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model.
Topics: Animals; Anticholesteremic Agents; Azetidines; Coronary Restenosis; Disease Models, Animal; Drug Combinations; Drug Implants; Drug-Eluting Stents; Ezetimibe; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Swine; Treatment Outcome | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex | 2010 |
Money, money, money.
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Simvastatin | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients: assessment by 13N-ammonia positron emission tomography.
Topics: Adenosine; Adolescent; Adult; Aged; Ammonia; Anticholesteremic Agents; Azetidines; Case-Control Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Humans; Male; Middle Aged; Myocardium; Nitrogen Isotopes; Positron-Emission Tomography; Prospective Studies; Risk Factors; Simvastatin | 2010 |
Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations.
Topics: Atorvastatin; Azetidines; Calibration; Drug Combinations; Drug Compounding; Drug Stability; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Hypolipidemic Agents; Molecular Structure; Pyrroles; Reproducibility of Results; Simvastatin; Solvents; Spectrophotometry, Ultraviolet; Tablets | 2011 |
Ezetimibe in diabetes: more than cholesterol lowering?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Managing residual risk in patients receiving statin therapy.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2010 |
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation | 2010 |
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial: comment on Ruggenenti et al.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2010 |
Development and validation of spectrophotometeric method for simultaneous determination of simvastatin and ezetimibe in tablet formulations.
Topics: Azetidines; Calibration; Chemistry, Pharmaceutical; Drug Combinations; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Reference Standards; Reproducibility of Results; Simvastatin; Spectrophotometry, Ultraviolet; Tablets | 2010 |
Comments regarding 'A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms'.
Topics: Anticholesteremic Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Azetidines; Biopsy; Drug Therapy, Combination; Ezetimibe; Humans; Interleukin-6; Matrix Metalloproteinase 9; Randomized Controlled Trials as Topic; Simvastatin | 2011 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
Heterozygous familial hypercholesterolemia case study.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Life Style; Male; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2010 |
Emphasizing the burden of proof: The American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cardiology; Carotid Arteries; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Evidence-Based Medicine; Expert Testimony; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Simvastatin | 2010 |
Ezetimibe and low density lipoprotein subfractions: an ongoing debate.
Topics: Anticholesteremic Agents; Azetidines; Chemical Fractionation; Cholesterol; Cholesterol, LDL; Dissent and Disputes; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Particle Size; Prognosis; Simvastatin | 2011 |
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Young Adult | 2011 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Azetidines; Caco-2 Cells; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymerase Chain Reaction; Pyrroles; RNA, Messenger; Simvastatin; Time Factors | 2011 |
Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Portugal; Simvastatin; Triglycerides | 2011 |
Managing residual risk in patients receiving statin therapy.
Topics: Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2011 |
Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Logistic Models; Male; Middle Aged; Patient Compliance; Retrospective Studies; Risk; Simvastatin; Treatment Outcome | 2011 |
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin | 2011 |
Statin-associated myasthenic weakness.
Topics: Anticholesteremic Agents; Azetidines; Cholinesterase Inhibitors; Electromyography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Muscle Weakness; Myasthenia Gravis; Simvastatin; Treatment Outcome | 2011 |
More on DSMBs.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Industry; Ezetimibe; Humans; Neoplasms; Simvastatin; United States | 2011 |
Managing residual risk in patients receiving statin therapy. Comment.
Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
SHARP: a stab in the right direction in chronic kidney disease.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin; Treatment Outcome | 2011 |
Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease.
Topics: Aged; Asia; Azetidines; Cholesterol; Cohort Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Effects of simvastatin, atorvastatin, ezetimibe, and ezetimibe + simvastatin combination on the inflammatory process and on the liver metabolic changes of arthritic rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Leukocyte Count; Leukocytes; Liver; Liver Function Tests; Perfusion; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
Left atrial systolic force in asymptomatic aortic stenosis.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Blood Pressure; Body Mass Index; Chi-Square Distribution; Echocardiography, Doppler; Ezetimibe; Female; Heart Atria; Heart Function Tests; Heart Rate; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Regression Analysis; Risk Factors; Simvastatin; Systole | 2011 |
Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease.
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Humans; Leg; Male; Peripheral Arterial Disease; Simvastatin | 2011 |
Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults.
Topics: Adult; Aged; Asian People; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Combinations; Drug Synergism; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Trial clouds use of niacin with a statin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure | 2011 |
[Nephrology].
Topics: Anticholesteremic Agents; Azathioprine; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Lupus Nephritis; Mycophenolic Acid; Nephrology; Renal Dialysis; Secondary Prevention; Simvastatin; Treatment Outcome | 2012 |
PTU induction provide quick screening of hypo and hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Antithyroid Agents; Azetidines; Cholesterol; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Propylthiouracil; Rats; Simvastatin | 2011 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
[The influence of ezetimibe and simvaststin on platelet aggregation and protein c system in patients with coronary heart disease and hypercholesterolemia].
Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Protein C; Simvastatin | 2012 |
Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biglycan; Cholesterol; Ezetimibe; Insulin Resistance; Lipoproteins; Male; Metabolic Syndrome; Rats; Simvastatin | 2012 |
Ezetimibe-Simvastatin, a pharmacodynamic interaction?
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, LDL; Drug Interactions; Ezetimibe; Humans; Interleukin-6; Simvastatin | 2013 |
[The SHARP study].
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Simvastatin | 2013 |
Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anticholesteremic Agents; Azetidines; Diabetes Mellitus; Drug Interactions; Ezetimibe; Glucose Transporter Type 4; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Simvastatin; Ubiquinone | 2013 |
Change in cholesterol absorption and synthesis markers in patients with coronary heart disease after combination therapy with simvastatin plus ezetimibe.
Topics: Adult; Aged; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin | 2013 |
Simultaneous determination of some cholesterol-lowering drugs in their binary mixture by novel spectrophotometric methods.
Topics: Absorption; Analysis of Variance; Anticholesteremic Agents; Azetidines; Ezetimibe; Powders; Simvastatin; Spectrophotometry; Tablets | 2013 |
HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe?
Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hypolipidemic Agents; Indoles; Niacin; Simvastatin | 2013 |
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency.
Topics: Aged; Azetidines; Case-Control Studies; Coronary Artery Disease; Ezetimibe; Female; Follow-Up Studies; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hypolipidemic Agents; Lipids; Macromolecular Substances; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Randomized Controlled Trials as Topic; Risk Factors; Serine Endopeptidases; Simvastatin | 2014 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Systematic approach to conformational sampling for assigning absolute configuration using vibrational circular dichroism.
Topics: Alkynes; Aprepitant; Azetidines; Benzoxazines; Camphor; Circular Dichroism; Computational Biology; Cyclohexane Monoterpenes; Cyclopropanes; Drug Discovery; Ezetimibe; Ibuprofen; Molecular Conformation; Monoterpenes; Morpholines; Pharmaceutical Preparations; Quantum Theory; Simvastatin; Statistical Distributions; Stereoisomerism | 2014 |
Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.
Topics: Animals; Azetidines; Benzophenones; Cholesterol; Diet; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Intestine, Small; Intramolecular Transferases; Liver; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Receptors, LDL; Simvastatin; Species Specificity | 2014 |
Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis; Azetidines; Cartilage, Articular; Disease Progression; Drug Therapy, Combination; Ezetimibe; Flow Cytometry; Freund's Adjuvant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Rats; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
C282Y-HFE gene variant affects cholesterol metabolism in human neuroblastoma cells.
Topics: Alleles; Androstenes; Azetidines; Cell Line, Tumor; Cell Survival; Cholesterol; Ezetimibe; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron; Membrane Proteins; Neuroblastoma; Oxidoreductases; Phenotype; Phosphotransferases (Alcohol Group Acceptor); Risk Factors; Simvastatin; Sphingolipids | 2014 |
Use of targeted exome sequencing in genetic diagnosis of Chinese familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Asian People; Azetidines; Child, Preschool; China; DNA Mutational Analysis; Drug Therapy, Combination; Exome; Ezetimibe; Genotype; Humans; Hypercholesterolemia; Male; Mutation; Pedigree; Phenotype; Simvastatin; Treatment Outcome | 2014 |
[Does ezetimibe combined with simvastatin increase the risk of renal failure].
Topics: Aged; Anticholesteremic Agents; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Male; Renal Insufficiency; Risk Factors; Simvastatin | 2014 |
Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Comorbidity; Coronary Artery Bypass; Ezetimibe; Female; Heart Valve Prosthesis Implantation; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Stroke | 2014 |
Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azetidines; Calcinosis; Cardiovascular Diseases; Case-Control Studies; Drug Therapy, Combination; Endoplasmic Reticulum; Ezetimibe; Humans; Ketocholesterols; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Transcription Factor CHOP; Vascular Diseases | 2014 |
The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Middle Aged; Polycystic Ovary Syndrome; Simvastatin; Testosterone | 2014 |
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin | 2014 |
Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Disease Progression; Ezetimibe; Female; Humans; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; United States | 2014 |
The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia.
Topics: Adipokines; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin | 2014 |
Two smart spectrophotometric methods for the simultaneous estimation of Simvastatin and Ezetimibe in combined dosage form.
Topics: Anticholesteremic Agents; Azetidines; Chemistry, Pharmaceutical; Drug Combinations; Drug Industry; Ezetimibe; Least-Squares Analysis; Limit of Detection; Models, Theoretical; Quality Control; Reproducibility of Results; Signal Processing, Computer-Assisted; Simvastatin; Software; Spectrophotometry; Spectrophotometry, Ultraviolet | 2015 |
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Body Mass Index; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Prospective Studies; Simvastatin; Waist Circumference | 2015 |
Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Survival; Cells, Cultured; Down-Regulation; Endothelium, Vascular; Ezetimibe; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Luminescence; MicroRNAs; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Real-Time Polymerase Chain Reaction; Simvastatin | 2015 |
[Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome | 2015 |
Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; United Kingdom | 2015 |
Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Simvastatin | 2015 |
Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism.
Topics: Analysis of Variance; Animals; Azetidines; Blotting, Western; Cholesterol; DNA Primers; Drug Evaluation, Preclinical; Drug Therapy, Combination; Ezetimibe; Gastrointestinal Tract; Gene Expression Regulation; Lactobacillus; Liver; Male; Metabolic Networks and Pathways; Mice; Mice, Inbred C57BL; Microbiota; Real-Time Polymerase Chain Reaction; Simvastatin; Sterol Regulatory Element Binding Protein 2 | 2015 |
[LDL cholesterol lowering therapy: no target value but personalised treatment].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2015 |
Zetia study keeps PCSK9s on approval course.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Drugs, Investigational; Ezetimibe; Humans; Outcome Assessment, Health Care; Simvastatin | 2015 |
Modulation of cholesterol-related gene expression by ergosterol and ergosterol-enriched extracts obtained from Agaricus bisporus.
Topics: Agaricus; Animals; beta-Glucans; Caco-2 Cells; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Diacylglycerol O-Acyltransferase; Diet, High-Fat; Down-Regulation; Ergosterol; Ezetimibe; Feces; Gene Expression Regulation; Hep G2 Cells; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Simvastatin; Sterol Regulatory Element Binding Protein 2; Sterols; Triglycerides; Up-Regulation | 2016 |
[The surprising (?) results of IMPROVE-IT].
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Congresses as Topic; Ezetimibe; Global Health; Humans; Hypercholesterolemia; Incidence; Italy; Meta-Analysis as Topic; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome; United States | 2015 |
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Patient Selection; Simvastatin | 2015 |
Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia.
Topics: Adiponectin; Aged; Animals; Anticholesteremic Agents; Blood Pressure; C-Reactive Protein; Drug Therapy, Combination; Ezetimibe; Fat Body; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Randomized Controlled Trials as Topic; Rats; Simvastatin; Single-Blind Method | 2015 |
Improve-it: Full disclosures?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Disclosure; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Simvastatin; Treatment Outcome | 2015 |
Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2015 |
Reply to comment on: Effects of ezetimibe/simvastatin combination on metabolic parameters by Prof. Moses S Elisaf.
Topics: Animals; Anticholesteremic Agents; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Simvastatin | 2016 |
Effects of ezetimibe/simvastatin combination on metabolic parameters.
Topics: Animals; Anticholesteremic Agents; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Simvastatin | 2016 |
Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; PCSK9 Inhibitors; Secondary Prevention; Simvastatin; Treatment Outcome | 2016 |
Effect of the Combination of Ezetimibe and Simvastatin on Gluconeogenesis and Oxygen Consumption in the Rat Liver.
Topics: Animals; Cyanides; Drug Combinations; Enzyme Inhibitors; Ezetimibe; Fructose-Bisphosphatase; Gluconeogenesis; Glucose-6-Phosphatase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Microsomes, Liver; Mitochondria, Liver; Oxygen Consumption; Proadifen; Rats; Rats, Sprague-Dawley; Simvastatin | 2016 |
Treatment of SPG5 with cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Ezetimibe; Follow-Up Studies; Humans; Hydroxycholesterols; Siblings; Simvastatin; Spastic Paraplegia, Hereditary | 2015 |
[The IMPROVE-IT trial].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
[The IMPROVE-IT trial showed no favorable effects on well-defined and clinically relevant endpoints].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
[Letter].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
An Informed and Activated Patient: Addressing Barriers in the Pathway From Education to Outcomes.
Topics: Anticholesteremic Agents; Educational Status; Ezetimibe; Female; Humans; Male; Renal Insufficiency, Chronic; Simvastatin | 2016 |
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Clinical Decision-Making; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Health Services for the Aged; Humans; Male; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Effects of Statins on the Development of Cataract-the Long Standing Debate.
Topics: Aortic Valve Stenosis; Cataract; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
PROVE-IT to IMPROVE-IT: Why LDL-C Goals Still Matter in Post-ACS Patients.
Topics: Acute Coronary Syndrome; Ezetimibe; Female; Humans; Male; Myocardial Infarction; Simvastatin | 2016 |
Simvastatin pretreatment enhances ischemia-induced neovascularization and blood flow recovery in streptozotocin-treated mice.
Topics: Animals; Blood Flow Velocity; Collateral Circulation; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelial Progenitor Cells; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Phosphorylation; Recovery of Function; Regional Blood Flow; Simvastatin; Streptozocin; Time Factors; Vascular Endothelial Growth Factor A; Vasodilation | 2016 |
Prevention of Cataract by Statins.
Topics: Aortic Valve Stenosis; Cataract; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels.
Topics: Adipokines; Adipose Tissue; Adult; Age Factors; Aged; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Retrospective Studies; Simvastatin | 2016 |
Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Se
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States | 2016 |
Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population.
Topics: Blood Chemical Analysis; Chromatography, Liquid; Ezetimibe; Humans; India; Limit of Detection; Reproducibility of Results; Simvastatin; Tandem Mass Spectrometry | 2016 |
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Blood Component Removal; Codon, Terminator; Combined Modality Therapy; Coronary Disease; DNA Mutational Analysis; Ezetimibe; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Myocardial Revascularization; Receptors, LDL; Simvastatin | 2016 |
Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Secondary Prevention; Simvastatin | 2016 |
Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Secondary Prevention; Simvastatin | 2016 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Female; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Uric Acid | 2016 |
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Male; Metabolic Syndrome; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2016 |
Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
Topics: Animals; Anticholesteremic Agents; Cell Line, Tumor; Cell Proliferation; Cholesterol; Drug Therapy, Combination; Ezetimibe; Feedback, Physiological; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Simvastatin; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Cell Adhesion; Cytokines; Drug Therapy, Combination; Ezetimibe; Inflammation; Knee Joint; Leukocyte Rolling; Leukocytes; Rats; Simvastatin | 2017 |
Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report.
Topics: Acute Kidney Injury; Aged; Colchicine; Ezetimibe; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Obesity; Rhabdomyolysis; Simvastatin; Treatment Outcome | 2017 |
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
Topics: Acute Coronary Syndrome; Aged; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Secondary Prevention; Simvastatin; Treatment Outcome | 2017 |
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Rosuvastatin Calcium; Simvastatin | 2017 |
How has the treatment of hypercholesterolemia in Poland changed over the last six years?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Poland; Registries; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Surveys and Questionnaires; Time Factors | 2017 |
[Development of the "Consensus guidelines for the use of drugs in renal failure"].
Topics: Consensus; Ezetimibe; Humans; Renal Insufficiency; Simvastatin | 2017 |
Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Registries; Simvastatin | 2017 |
A Versatile Liquid Chromatographic Method for the Simultaneous Determination of Metformin, Sitagliptin, Simvastatin, and Ezetimibe in Different Dosage Forms.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Ezetimibe; Limit of Detection; Metformin; Simvastatin; Sitagliptin Phosphate | 2018 |
Ezetimibe, Risk Stratification, and Secondary Prevention.
Topics: Anticholesteremic Agents; Ezetimibe; Secondary Prevention; Simvastatin | 2017 |
Reply: Ezetimibe, Risk Stratification, and Secondary Prevention.
Topics: Anticholesteremic Agents; Ezetimibe; Secondary Prevention; Simvastatin | 2017 |
Chemometric-Assisted Spectrophotometric Method for the Simultaneous Quantitative Determination of Ezetimibe and Simvastatin in Their Combined Dosage Forms.
Topics: Algorithms; Capsules; Drug Combinations; Ezetimibe; Least-Squares Analysis; Limit of Detection; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; Spectrophotometry, Ultraviolet | 2018 |
Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Monocytes; RNA, Messenger; Simvastatin | 2017 |
SPG5 siblings with different phenotypes showing reduction of 27-hydroxycholesterol after simvastatin-ezetimibe treatment.
Topics: Adult; Anticholesteremic Agents; Brain; Cytochrome P450 Family 7; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxycholesterols; Middle Aged; Phenotype; Siblings; Simvastatin; Spastic Paraplegia, Hereditary; Steroid Hydroxylases; Treatment Outcome | 2017 |
Comment on the original paper entitled "The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients".
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Simvastatin; Treatment Outcome | 2018 |
Is the decrease of triglyceride level after acute myocardial infarction within a month by the effect of combination therapy of Ezetimibe and Simvastatin.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Simvastatin; Treatment Outcome; Triglycerides | 2018 |
If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis.
Topics: Acute Coronary Syndrome; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2018 |
Statin-induced myopathy prevented by creatine administration.
Topics: Aged; Amaurosis Fugax; Anticholesteremic Agents; Carotid Stenosis; Cholesterol, LDL; Creatine; Drug Therapy, Combination; Ezetimibe; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myalgia; Pyrimidines; Simvastatin; Treatment Outcome | 2018 |
Simvastatin and Simvastatin-Ezetimibe Improve the Neurological Function and Attenuate the Endothelial Inflammatory Response after Spinal Cord Injury in Rat.
Topics: Animals; Anticholesteremic Agents; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Inflammation; Male; Motor Activity; Neurons; Rats; Rats, Sprague-Dawley; Recovery of Function; Simvastatin; Spinal Cord Injuries | 2019 |
Theoretical Model for the Structural Relaxation Time in Coamorphous Drugs.
Topics: Calorimetry, Differential Scanning; Dielectric Spectroscopy; Drug Compounding; Drug Liberation; Ezetimibe; Kinetics; Models, Molecular; Pyrrolidines; Simvastatin; Solubility; Temperature; Vinyl Compounds; Vitrification | 2019 |
Intensive Lipid Lowering in Elderly Patients.
Topics: Acute Coronary Syndrome; Aged; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Simvastatin | 2019 |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2020 |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2020 |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2020 |
Polypharmacy induced myositis.
Topics: Aged, 80 and over; Clarithromycin; Drug Interactions; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myositis; Polypharmacy; Pregabalin; Simvastatin | 2020 |
Significant effect of simvastatin and/or ezetimibe-loaded nanofibers on the healing of femoral defect: An experimental study.
Topics: Animals; Bone Density; Ezetimibe; Femur; Fracture Healing; Male; Nanofibers; Osteoprotegerin; Rats, Wistar; Simvastatin | 2020 |
Sustainable environment-friendly quantitative determination of three anti-hyperlipidemic statin drugs and ezetimibe in binary mixtures by first derivative Fourier transform infrared (FTIR) spectroscopy.
Topics: Atorvastatin; Drug Combinations; Ezetimibe; Green Chemistry Technology; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Limit of Detection; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared; Tablets | 2020 |
Tendonopathy Due to Simvastatin and Ezetimibe, Amyloidosis or Both?
Topics: Amyloidosis; Cardiomyopathies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Simvastatin; Tendinopathy | 2020 |
A prospective mechanism and source of cholesterol uptake by Plasmodium falciparum-infected erythrocytes co-cultured with HepG2 cells.
Topics: Anticholesteremic Agents; Cholesterol; Erythrocytes; Ezetimibe; Fibric Acids; Hep G2 Cells; Humans; Hypolipidemic Agents; Plasmodium falciparum; Simvastatin | 2021 |
[A report of successful management with simvastatin plus ezetimibe in alopecia areata].
Topics: Adult; Alopecia Areata; Ezetimibe; Female; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; Simvastatin; Young Adult | 2020 |
Simvastatin-Ezetimibe enhances growth factor expression and attenuates neuron loss in the hippocampus in a model of intracerebral hemorrhage.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Hippocampus; Intercellular Signaling Peptides and Proteins; Male; Maze Learning; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Simvastatin | 2021 |
LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Registries; Rosuvastatin Calcium; Simvastatin | 2022 |
Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenotype; Registries; Rosuvastatin Calcium; Simvastatin; Spain; Treatment Outcome | 2021 |
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Simvastatin | 2021 |
Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study.
Topics: Atorvastatin; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Compliance; Simvastatin | 2021 |
Alopecia Universalis after Treatment with Simvastatin and Ezetimibe: Affects on Family.
Topics: Alopecia Areata; Atorvastatin; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2022 |
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Ezetimibe; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Mammals; Simvastatin; Zebrafish | 2022 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Simvastatin rescues vascular health by targeting epigenetic-regulated endothelial-to-mesenchymal transition: a revival of pleiotropic effects?
Topics: Cells, Cultured; Endothelium, Vascular; Epigenesis, Genetic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2023 |